Liminatus Pharma, Inc.

Healthcare · Biotechnology · United States

Last price 2.82 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.79M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.